{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:53:17Z","timestamp":1771469597552,"version":"3.50.1"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/mjt.0b013e3181ec9eb2","type":"journal-article","created":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T10:32:38Z","timestamp":1284114758000},"page":"638-653","source":"Crossref","is-referenced-by-count":11,"title":["Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus"],"prefix":"10.1097","volume":"20","author":[{"given":"Margaret C.","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Cecilia","family":"Lansang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-10-20210202","first-page":"1","article-title":"Economic costs of diabetes in the U.S in 2007.","volume":"31","year":"2008","journal-title":"Diab Care"},{"key":"R4-10-20210202","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":". Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"32","author":"Nathan","year":"2009","journal-title":"Diab Care"},{"key":"R5-10-20210202","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00257346","article-title":"Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from gut extracts by immunoadsorption.","volume":"24","author":"Ebert","year":"1983","journal-title":"Diabetologia"},{"key":"R6-10-20210202","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":". Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"key":"R7-10-20210202","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man.","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"R8-10-20210202","first-page":"1421","article-title":". The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) ad glucagon-like peptide-1 (7-36) amide in humans.","volume":"101","author":"Elahi","year":"1998","journal-title":"J Clin Invest"},{"key":"R9-10-20210202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":". Reduced incretin effect in type 2 diabetes.","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"R10-10-20210202","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":". Reduced postprandial concentrations of intact biological active glucagon-like peptide 1 in type 2 diabetes.","volume":"50","author":"Vilsboll","year":"2001","journal-title":"Diabetes"},{"key":"R11-10-20210202","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":". Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-10-20210202","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-2002-23199","article-title":". Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non-insulin dependent) diabetes.","volume":"34","author":"Lugari","year":"2002","journal-title":"Horm Metab Res"},{"key":"R13-10-20210202","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":". Preserved incretin activity of GLP-1 but not of synthetic human GIP in patients with type 2 diabetes mellitus.","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"R14-10-20210202","first-page":"270","article-title":". Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.","volume":"15","author":"Gutniak","year":"1992","journal-title":"New Engl J Med"},{"key":"R15-10-20210202","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/diacare.15.2.270","article-title":". Insulinotropic action of glucagon-like peptide-1 (7,37) in diabetic and nondiabetic subjects.","volume":"15","author":"Nathan","year":"1992","journal-title":"Diab Care"},{"key":"R16-10-20210202","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":". Exenatide improves insulin sensitivity and beta cell mass in insulin-resistant obese fafa Zucker rats independent of glycemia and body weight.","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"key":"R17-10-20210202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1566524053766004","article-title":"Type 2 diabetes, insulin secretion and beta cell mass.","volume":"5","author":"Ahren","year":"2005","journal-title":"Curr Mol Med"},{"key":"R18-10-20210202","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","article-title":". Glucagon-like peptide and exedin-4 stimulate beta cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.","volume":"50","author":"Tourrel","year":"2001","journal-title":"Diabetes"},{"key":"R19-10-20210202","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":". Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","volume":"27","author":"Buse","year":"2004","journal-title":"Diab Care"},{"key":"R20-10-20210202","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":". Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diab Care"},{"key":"R21-10-20210202","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":". Effects of exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","volume":"28","author":"Kendall","year":"2005","journal-title":"Diab Care"},{"key":"R22-10-20210202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":". The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"key":"R23-10-20210202","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":". Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Therap"},{"key":"R24-10-20210202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":". Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R25-10-20210202","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":". Exenatide vs. insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"R26-10-20210202","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":". A comparison of twice-daily exenatide and biphasic insulin apart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiorly study.","volume":"50","author":"Naunk","year":"2007","journal-title":"Diabetologia"},{"key":"R27-10-20210202","doi-asserted-by":"crossref","first-page":"363","DOI":"10.18553\/jmcp.2008.14.4.363","article-title":"Managed care perspective on three new agents for Type 2 Diabetes.","volume":"14","author":"VanDeKoppel","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"R29-10-20210202","first-page":"1970","article-title":"Exenatide and rare adverse events.","volume":"358","author":"Ahmad","year":"2008","journal-title":"New Engl J Med"},{"key":"R30-10-20210202","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":". Effects of once weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.","volume":"30","author":"Kim","year":"2007","journal-title":"Diab Care"},{"key":"R31-10-20210202","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":". Exenatide once weekly vs. twice daily for the treatment of type 2 diabetes: a randomized, open label, non-inferiority study.","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"R32-10-20210202","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":". The pharmacokinetics, pharmacodynamics, safety and tolerability of NN221, a new long-acting GLP-1 derivative, in healthy men.","volume":"45","author":"Agerso","year":"2002","journal-title":"Diabetologia"},{"key":"R33-10-20210202","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1345\/aph.1M134","article-title":"Liraglutide: a once daily incretin mimetic for treatment of type 2 diabetes mellitus.","volume":"43","author":"Neumiller","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R34-10-20210202","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":". and the LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU).","volume":"26","author":"Marre","year":"2009","journal-title":"Diab Med"},{"key":"R35-10-20210202","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":". and the LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetTZD).","volume":"32","author":"Zinman","year":"2009","journal-title":"Diab Care"},{"key":"R36-10-20210202","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":". and the LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.","volume":"32","author":"Nauck","year":"2009","journal-title":"Diab Care"},{"key":"R37-10-20210202","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":". and the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial.","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"R38-10-20210202","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":". and the liraglutide effect and action in Diabetes 5 (LEAD-5) metSU Study Group. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 metSU): a randomized controlled trial.","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"R39-10-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":". and the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6).","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"R41-10-20210202","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":". for the Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidylpeptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2diabetes mellitus.","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"key":"R42-10-20210202","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":". and the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.","volume":"29","author":"Aschner","year":"2006","journal-title":"Diab Care"},{"key":"R43-10-20210202","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-2006-944546","article-title":". Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.","volume":"38","author":"Pratley","year":"2006","journal-title":"Horm Metab Res"},{"key":"R44-10-20210202","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diabres.2006.12.009","article-title":". Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes.","volume":"76","author":"Pi-Sunyer","year":"2007","journal-title":"Diab Res Clin Prac"},{"key":"R45-10-20210202","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":". Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes.","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R46-10-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":". for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone.","volume":"9","author":"Nauck","year":"2007","journal-title":"Diab Obes Metab"},{"key":"R47-10-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/dc06-1815","article-title":". Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.","volume":"30","author":"Rosenstock","year":"2007","journal-title":"Diab Care"},{"key":"R48-10-20210202","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1464-5491.2007.02191.x","article-title":". Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes.","volume":"24","author":"Schweizer","year":"2007","journal-title":"Diab Med"},{"key":"R49-10-20210202","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":". and the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diab Care"},{"key":"R50-10-20210202","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/dc06-1732","article-title":". Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.","volume":"30","author":"Bosi","year":"2007","journal-title":"Diab Care"},{"key":"R51-10-20210202","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":". The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone.","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diab Care"},{"key":"R52-10-20210202","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":". for the Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diab Obes Metab"},{"key":"R53-10-20210202","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1463-1326.2008.00859.x","article-title":". Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.","volume":"10","author":"Garber","year":"2008","journal-title":"Diab Obes Metab"},{"key":"R54-10-20210202","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1742-1241.2009.02143.x","article-title":". and the CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with up titration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial.","volume":"63","author":"Chacra","year":"2009","journal-title":"Int J Clin Prac"},{"key":"R55-10-20210202","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"; for the Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Therap"},{"key":"R56-10-20210202","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1463-1326.2006.00684.x","article-title":". Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.","volume":"9","author":"Garber","year":"2007","journal-title":"Diab Obes Metab"},{"key":"R57-10-20210202","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"Chen R; and the CV181-013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.","volume":"94","author":"Hollander","year":"2009","journal-title":"J Clin Endocrin Metab"},{"key":"R58-10-20210202","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":". Addition of vildagliptin to insulin improves glycemic control in type 2 diabetes.","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"key":"R59-10-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.","volume":"298","author":"Amori","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R61-10-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3810\/pgm.2010.01.2108","article-title":"Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.","volume":"122","author":"LaSalle","year":"2010","journal-title":"Postgrad Med"},{"key":"R62-10-20210202","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":". Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"R63-10-20210202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":". The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism"},{"key":"R64-10-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/jsbi.1997.3858","article-title":". Polymorphic fibrillar assembly of human amylin.","volume":"119","author":"Goldsbury","year":"1999","journal-title":"J Struct Biol"},{"key":"R65-10-20210202","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin.","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev Res"},{"key":"R66-10-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1054-3589(05)52002-7","article-title":"Tissue expression and secretion of amylin.","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"R67-10-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1568005310202010063","article-title":"Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.","volume":"2","author":"Baron","year":"2002","journal-title":"Curr Drug Targ Imm End Metab Disord"},{"issue":"Suppl 1","key":"R68-10-20210202","first-page":"A113","article-title":". Effects of six months of administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes.","volume":"48","author":"Fineman","year":"1999","journal-title":"Diabetes"},{"key":"R69-10-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ecl.2004.11.006","article-title":"Novel pharmacologic agents for type 2 diabetes.","volume":"34","author":"Uwaifo","year":"2005","journal-title":"Endocrin Metab Clin North Am"},{"issue":"Suppl 1","key":"R70-10-20210202","first-page":"A109","article-title":". Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks.","volume":"49","author":"Gottlieb","year":"2000","journal-title":"Diabetes"},{"key":"R71-10-20210202","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":". Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial.","volume":"21","author":"Ratner","year":"2004","journal-title":"Diab Med"},{"key":"R72-10-20210202","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":". A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.","volume":"29","author":"Edelman","year":"2006","journal-title":"Diab Care"},{"key":"R73-10-20210202","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":". Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.","volume":"21","author":"Thompson","year":"1998","journal-title":"Diab Care"},{"key":"R74-10-20210202","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":". Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycemic targets.","volume":"5","author":"Hollander","year":"2003","journal-title":"Diab Obes Metab"},{"key":"R75-10-20210202","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":". Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.","volume":"26","author":"Hollander","year":"2003","journal-title":"Diab Care"},{"key":"R77-10-20210202","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","article-title":". Results of the glucose-lowering effect of Welchol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.","volume":"29","author":"Zieve","year":"2007","journal-title":"Clin Therap"},{"key":"R78-10-20210202","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/archinte.168.18.1975","article-title":". Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.","volume":"168","author":"Bays","year":"2008","journal-title":"Arch Int Med"},{"key":"R79-10-20210202","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc08-0283","article-title":". Colesevelam HCI improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.","volume":"31","author":"Fonseca","year":"2008","journal-title":"Diab Care"},{"key":"R80-10-20210202","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.168.14.1531","article-title":". Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.","volume":"168","author":"Goldberg","year":"2008","journal-title":"Arch Int Med"},{"key":"R81-10-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000199586","article-title":"Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids.","volume":"38","author":"Thomson","year":"1987","journal-title":"Digestion"},{"key":"R82-10-20210202","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF01071888","article-title":"Conjugated dihydroxy bile salt inhibition of glucose influx in rat jejunum in vitro.","volume":"22","author":"Feldman","year":"1977","journal-title":"Am J Digest Dis"},{"key":"R83-10-20210202","first-page":"981","article-title":"Kuipers F, et al..","volume":"146","author":"Cariou","year":"2005","journal-title":"Farnesoid X receptor: a new player in glucose metabolism Endocrinology"},{"key":"R84-10-20210202","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscl Thromb Vascul Biol"},{"key":"R86-10-20210202","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/350354a0","article-title":". Glucosegalactose malabsorption caused by a defect in the Naglucose cotransporter.","volume":"350","author":"Turk","year":"1991","journal-title":"Nature"},{"key":"R87-10-20210202","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":". Molecular analysis of the SGLT2 gene in patients with renal glucosuria.","volume":"14","author":"Santer","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R90-10-20210202","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":". Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Therap"},{"key":"R91-10-20210202","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":". Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Therap"},{"key":"R92-10-20210202","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":". Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.","volume":"32","author":"List","year":"2009","journal-title":"Diab Care"},{"key":"R94-10-20210202","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000059685","article-title":"D-tagatosea novel low-calorie bulk sweetener with probiotic properties.","volume":"85","author":"Bertelsen","year":"1999","journal-title":"World Rev Nutr Diet"},{"key":"R95-10-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0891-5849(96)00331-0","article-title":". Fructose and tagatose protect against oxidative cell injury by iron chelation.","volume":"22","author":"Valeri","year":"1997","journal-title":"Free Rad Biol Med"},{"key":"R96-10-20210202","first-page":"285","article-title":"Tagatose: from a sweetener to a new diabetic medication Exp Opin Inv Drugs.","volume":"19","author":"Espinosa","year":"2010","journal-title":""},{"key":"R97-10-20210202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1463-1326.1999.00039.x","article-title":"D-tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes.","volume":"1","author":"Donner","year":"1999","journal-title":"Diab Obes Metab"},{"key":"R98-10-20210202","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1053\/meta.2000.7724","article-title":". D-tagatose, a stereoisomer of D-fructose, increases blood uric acid concentration.","volume":"49","author":"Buemann","year":"2000","journal-title":"Metabolism"},{"issue":"Suppl 1","key":"R100-10-20210202","first-page":"A110","article-title":"The metabolic effects of dietary supplementation with D-tagatose in patients with type 2 diabetes.","volume":"55","author":"Donner","year":"2006","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"R101-10-20210202","first-page":"125A","article-title":"D-tagatose: a novel therapeutic adjunct for non-insulin dependent diabetes (abstract).","volume":"45","author":"Donner","year":"1996","journal-title":"Diabetes"},{"issue":"Pt 2","key":"R102-10-20210202","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1006\/rtph.1998.1262","article-title":". 90-Day oral toxicity study of D-tagatose in rats.","volume":"29","author":"Kruger","year":"1999","journal-title":"Regul Toxicol Pharmacol"},{"key":"R104-10-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/rtph.2001.1470","article-title":". Effect of oral D-tagatose on liver volume and hepatic glycogen accumulation in healthy male volunteers.","volume":"33","author":"Boesch","year":"2001","journal-title":"Regul Toxicol Pharmacol"},{"issue":"Pt 2","key":"R105-10-20210202","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1006\/rtph.1998.1264","article-title":". Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans.","volume":"29","author":"Saunders","year":"1999","journal-title":"Regul Toxicol Pharmacol"},{"key":"R106-10-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1463-1326.2007.00799.x","article-title":"Tagatose, a new antidiabetic and obesity control drug.","volume":"10","author":"Lu","year":"2008","journal-title":"Diab Obes Metab"},{"key":"R108-10-20210202","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.0000047525.58618.3C","article-title":"; and the Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions.","volume":"107","author":"Tardif","year":"2003","journal-title":"Circulation"},{"key":"R109-10-20210202","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2006.11.039","article-title":"; and the CART-2 Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.","volume":"197","author":"Tardif","year":"2008","journal-title":"Atherosclerosis"},{"key":"R111-10-20210202","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2337\/diab.40.4.405","article-title":"Role of oxidative stress in development of complications in diabetes.","volume":"40","author":"Baynes","year":"1991","journal-title":"Diabetes"},{"key":"R112-10-20210202","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/13543780902849244","article-title":"Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects.","volume":"18","author":"Muldrew","year":"2009","journal-title":"Exp Opin Invest Drugs"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201311000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:51:37Z","timestamp":1740505897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201311000-00010"}},"subtitle":["Incretin-Based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol"],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181ec9eb2","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}